Streetbeat News

Products Services

ELDN

Eledon Pharmaceuticals announced results from its ongoing Phase 1b open-label trial evaluating tegoprubart for the prevention of rejection in patients undergoing de novo kidney transplantation. This news has led to a decrease in the company's share price.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 4:41 pm

ACLX

Arcellx Inc (NASDAQ: ACLX) announced new clinical data from its Phase 1 study of CART-ddBCMA in patients with relapsed or refractory multiple myeloma. The data shows a 100% overall response rate (ORR) in all patients. The stock is trading higher by 17.30% at $40.35.

Portfolio Pulse from Vandana Singh

November 02, 2023 | 4:39 pm

PBLA

Panbela Therapeutics Inc's stock is trading higher following the publication of preclinical and clinical data from studies of CPP-1X in recent-onset type 1 diabetes. The data, published in Cell Reports Medicine, showed that CPP-1X may preserve β cell function and is a safe, oral treatment option. The company's shares are up 31.80% at $1.05.

Portfolio Pulse from Vandana Singh

November 02, 2023 | 4:36 pm

META

Meta Platforms is launching a new A/B testing tool for Reels that allows creators to test different captions and thumbnails on mobile devices. This move is aimed at enhancing user engagement and content creation on the platform.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 4:36 pm

SBFM

Sunshine Biopharma has terminated its research agreement with Jewish General Hospital following unfavorable lab results on testing of its anti-cancer drug, Adva-27a. The company has paused the IND-enabling studies of Adva-27a pending a review of the possibility of chemical modification of the compound.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 4:25 pm

ACXP

Acurx Pharmaceuticals Inc's stock is trading lower after the company published efficacy results from a Phase 2 trial. The company had decided to terminate the Phase 2b vancomycin-controlled trial segment early due to high observed clinical cure rate and no emerging safety concerns. The clinical cure rate for ibezapolstat, to treat C. difficile Infection (CDI), was projected to be at least 90%. Other factors, including the cost and the challenging enrollment due to the COVID-19 pandemic, also influenced the decision. The stock is down more than 31%.

Portfolio Pulse from Vandana Singh

November 02, 2023 | 4:12 pm

ATHM

Autohome Inc reported Q3 2023 revenues of $261.2 million, up 3.4% YoY, but slightly below the consensus of $261.7 million. The company's adjusted earnings per ADS of $0.67 beat the consensus of $0.60. The company is expanding its Autohome Energy Space stores and integrating its used car business to tap into new energy vehicles opportunities. The stock has lost 18.4% YTD but is up by 1.25% at $26.56 on the last check Thursday.

Portfolio Pulse from Anusuya Lahiri

November 02, 2023 | 4:08 pm

ALPN

Alpine Immune Sciences Inc (NASDAQ:ALPN) presented the first clinical data of povetacicept in autoimmune glomerulonephritis at the American Society of Nephrology Kidney Week. The treatment showed clinically meaningful improvements in proteinuria and a significant reduction in disease-related biomarkers. The drug has been well tolerated with no severe infections reported. Following the news, ALPN shares are up 39.35% at $14.66.

Portfolio Pulse from Vandana Singh

November 02, 2023 | 4:04 pm

KRON

Kronos Bio, Inc. (NASDAQ:KRON) has presented positive preliminary data from the phase 1 dose escalation portion of the ongoing phase 1/2 KB-0742 study at the Connective Tissue Oncology Society annual meeting. The data shows that KB-0742 demonstrated on-mechanism, single agent anti-tumor activity and a manageable safety profile in heavily pre-treated patients with transcriptionally addicted solid tumors. The preliminary analysis included 28 patients who received doses from 10 mg up to 60 mg. The most prevalent treatment-emergent adverse events included nausea, vomiting and fatigue, all of which were grade 1/2.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 4:02 pm

XPEV

XPeng Inc's shares are trading higher by 8.3% despite no company-specific news. The company recently announced a record high in vehicle deliveries for October 2023, with 20,002 Smart EVs delivered, marking a 31% increase from the previous month and a 292% increase compared to the previous year. XPeng also unveiled its go-to-market plan for its advanced driver-assistance system (ADAS) called XNGP, with plans to expand its deployment in 50 cities by year-end.

Portfolio Pulse from Henry Khederian

November 02, 2023 | 3:48 pm